Leveraging the lessons learned from AN-1792, numerous active immunotherapies against Aβ, Tau, and αSyn have been developed over the last two decades for AD or PD, some of which have entered clinical testing [43,73,74,75,76,77]. The gene discussed is MAPT; the disease is Alzheimer disease.